SCHEMBL911091

SCHEMBL911091

O=C(C1CCCC1)N1CCNCC1

nearest known ligand 0.83

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.83
CHRNA3 P32297 3/20 0.83
CHRNA4 P43681 3/20 0.83
CHRNB3 Q05901 3/20 0.83
CHRNA6 Q15825 3/20 0.83
ALDH1A1 P00352 3/20 0.68
TSHR P16473 1/20 0.68
KMT2A Q03164 1/20 0.58
HPGD P15428 1/20 0.56
HSD11B1 P28845 4/20 0.52
LMNA P02545 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
CA2 P00918 2/20 0.48
CHKA P35790 1/20 0.48
HSD11B2 P80365 1/20 0.47
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA9 Q16790 1/20 0.45
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22672736 0.98 CHRNB2 (0.80) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
Ammonia Solution, Strong SCHEMBL27973853 0.98 CHRNB2 (0.80) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL4630620 0.98 CHRNB2 (0.80) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL22672737 0.98 CHRNB2 (0.80) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL7787652 0.98 CHRNB2 (0.80) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL930742 0.98 CHRNB2 (0.80) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL22672738 0.98 CHRNB2 (0.80) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
Hydrochloric Acid SCHEMBL2248932 0.96 CHRNB2 (0.77) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL911817 0.96 CHRNB2 (0.83) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL8314 0.91 CHRNB2 (1.00) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168084-B2 Purine based compounds as toll-like receptor 9 antagonist COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2021-11-09 US claimed
EP-3707140-B1 PURINE BASED COMPOUNDS AS TOLL-LIKE RECEPTOR 9 ANTAGONISTS COUNCIL SCIENT IND RES (IN) 2021-10-13 EP claimed
US-20200347062-A1 PURINE BASED COMPOUNDS AS TOLL-LIKE RECEPTOR 9 ANTAGONIST COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-11-05 US claimed
EP-3707140-A1 PURINE BASED COMPOUNDS AS TOLL-LIKE RECEPTOR 9 ANTAGONIST Council of Scientific and Industrial Research (IN) 2020-09-16 EP claimed
WO-2025101892-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS AND USES THEREOF Astellas Engineered Small Molecules US, Incorporated (US) 2025-05-15 WO disclosed
WO-2025082731-A1 INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA MOSANNA THERAPEUTICS AG (CH) 2025-04-24 WO disclosed
CN-119143715-B Diaryl methylpiperazine compound and preparation method, pharmaceutical composition and application thereof 天津匠新致成科技有限公司 2025-03-14 CN disclosed
EP-4479138-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 EP disclosed
CN-119143715-A Diaryl methylpiperazine compound and preparation method, pharmaceutical composition and application thereof 天津匠新致成科技有限公司 2024-12-17 CN disclosed
EP-3969450-B1 QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS SUZHOU FOUR HEALTH PHARMACEUTICALS CO LTD (CN) 2023-10-25 EP disclosed
WO-2023154519-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-17 WO disclosed
CN-113636970-B Isoindolone compound, preparation method and application thereof 河北康泰药业有限公司 2023-05-23 CN disclosed
US-6262059-B1 Method of treating a patient having precancerous lesions with quinazoline derivatives CELL PATHWAYS, INC. 2001-07-17 US disclosed
US-6235747-B1 NITRIC OXIDE SYNTHASE INHIBITOR PFIZER INC. 2001-05-22 US disclosed
CN-1215391-A 6-phenylpyridyl-2-amine derivatives PFIZER (US) 1999-04-28 CN disclosed
EP-0891332-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES PFIZER INC. (US) 1999-01-20 EP disclosed
WO-1997036871-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES PFIZER INC. (US) 1997-10-09 WO disclosed
WO-1979000166-A1 CYANOCARBOXAMIDINES AND QUINAZOLINE PROCESS BRISTOL MYERS CO (US) 1979-04-05 WO disclosed
US-4138561-A Cyanocarboxamidines and quinazoline process BRISTOL-MYERS COMPANY (US) 1979-02-06 US disclosed
US-4060615-A ANTIHYPERTENSIVE, PHOSPHODIESTERASE INHIBITOR MEAD JOHNSON & COMPANY (US) 1977-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168084-B2 Purine based compounds as toll-like receptor 9 antagonist TLR9, TLR1, TLR7 CHRNB2 2830/4885CHRNA3 2792/4885CHRNA4 2420/4885
US-20200347062-A1 PURINE BASED COMPOUNDS AS TOLL-LIKE RECEPTOR 9 ANTAGONIST TLR9, TLR1, TLR7 CHRNB2 2714/4885CHRNA3 2711/4885CHRNA4 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.